Stock Scorecard
Stock Summary for Coherus Biosciences Inc (CHRS) - $2.25 as of 5/7/2024 8:43:55 PM EST
Total Score
10 out of 29
Currently on the following lists
Small Cap Stock List
Tim's Recommendation
Possible Buy
Growth List Algorithm Criteria for CHRS
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for CHRS
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for CHRS
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for CHRS
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for CHRS
Financial Details for CHRS
Company Overview |
|
---|---|
Ticker | CHRS |
Company Name | Coherus Biosciences Inc |
Country | USA |
Description | Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilars and immuno-oncology market primarily in the United States. The company is headquartered in Redwood City, California. |
Sector Name | LIFE SCIENCES |
Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
Most Recent Quarter | 12/31/2023 |
Next Earnings Date | 6/6/2024 |
Stock Price History |
|
Last Day Price | 2.25 |
Last Day Price Updated | 5/7/2024 8:43:55 PM EST |
Last Day Volume | 656,269 |
Average Daily Volume | 1,764,391 |
52-Week High | 6.52 |
52-Week Low | 1.43 |
Last Price to 52 Week Low | 57.34% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 97.93 |
Sector PE | 55.58 |
5-Year Average PE | -1.55 |
Free Cash Flow Ratio | 2.16 |
Industry Free Cash Flow Ratio | 20.60 |
Sector Free Cash Flow Ratio | 31.79 |
Current Ratio Most Recent Quarter | 1.43 |
Total Cash Per Share | 1.04 |
Book Value Per Share Most Recent Quarter | -1.72 |
Price to Book Ratio | 73.19 |
Industry Price to Book Ratio | 7.49 |
Sector Price to Book Ratio | 22.19 |
Price to Sales Ratio Twelve Trailing Months | 0.98 |
Industry Price to Sales Ratio Twelve Trailing Months | 9.30 |
Sector Price to Sales Ratio Twelve Trailing Months | 5.15 |
Share Statistics |
|
Total Shares Outstanding | 113,498,000 |
Market Capitalization | 255,370,500 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Dividend Aristocrat? | False |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | -75.50% |
Annual Earnings Growth | 18.46% |
Reported EPS 12 Trailing Months | -2.53 |
Reported EPS Past Year | 0.00 |
Reported EPS Prior Year | -2.16 |
Net Income Twelve Trailing Months | -237,892,000 |
Net Income Past Year | -237,892,000 |
Net Income Prior Year | -291,754,000 |
Quarterly Revenue Growth YOY | 101.80% |
5-Year Revenue Growth | 156.38% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 117,748,000 |
Total Cash Past Year | 117,748,000 |
Total Cash Prior Year | 191,681,000 |
Net Cash Position Most Recent Quarter | -109,140,000 |
Net Cash Position Past Year | -109,140,000 |
Long Term Debt Past Year | 226,888,000 |
Long Term Debt Prior Year | 225,575,000 |
Total Debt Most Recent Quarter | 226,888,000 |
Equity to Debt Ratio Past Year | -5.78 |
Equity to Debt Ratio Most Recent Quarter | -5.78 |
Total Stockholder Equity Past Year | -193,425,000 |
Total Stockholder Equity Prior Year | -137,418,000 |
Total Stockholder Equity Most Recent Quarter | -193,425,000 |
Options |
|
Put/Call Ratio | 1.16 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | -0.05 |
MACD Signal | -0.07 |
20-Day Bollinger Lower Band | 1.83 |
20-Day Bollinger Middle Band | 2.43 |
20-Day Bollinger Upper Band | 3.03 |
Beta | 0.51 |
RSI | 53.62 |
50-Day SMA | 3.32 |
200-Day SMA | 10.61 |
System |
|
Modified | 5/6/2024 9:05:19 PM EST |